La Jolla Pharmaceutical Valuation
Is LJPC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of LJPC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: LJPC ($6.22) cotiza por debajo de nuestra estimación de valor razonable ($29.08)
Muy por debajo del valor justo: LJPC cotiza por debajo de su valor razonable en más de un 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LJPC?
Other financial metrics that can be useful for relative valuation.
| What is LJPC's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$155.11m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.1x |
| Enterprise Value/EBITDA | -304.6x |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does LJPC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.4x | ||
SPRO Spero Therapeutics | 4.3x | -2.9% | US$96.4m |
EGRX Eagle Pharmaceuticals | 4.9x | n/a | US$61.9m |
PLX Protalix BioTherapeutics | 10.9x | 96.5% | US$91.3m |
VNDA Vanda Pharmaceuticals | 89.7x | -147.9% | US$237.1m |
LJPC La Jolla Pharmaceutical | 39.1x | 59.0% | US$155.1m |
Price-To-Earnings vs. similares: LJPC es caro según su Ratio Price-To-Earnings (39.1x) en comparación con la media de sus homólogos (24x).
Price to Earnings Ratio vs Industry
How does LJPC's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs. Industria: LJPC es caro en función de su Ratio Price-To-Earnings (39.1x) en comparación con la media del sector US Biotechs (18.7x).
Price to Earnings Ratio vs Fair Ratio
What is LJPC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.1x |
| Fair PE Ratio | 42.1x |
PM vs. Ratio Justo: LJPC es un buen valor basado en su Ratio Price-To-Earnings (39.1x) comparado con el Ratio estimado Fair Price-To-Earnings (42.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.